MediWound (MDWD) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Company overview and product portfolio

• Operates as a late-stage biologic company with an FDA-approved, profitable drug and a Phase III asset targeting a multi-billion dollar market.

• NexoBrid is approved in over 40 countries, commercialized in the US, Europe, and Japan, and removes burn eschar rapidly without surgery.

• EscharEx, in Phase III for chronic wounds, targets a $2.5 billion US market and is supported by global partnerships and recent manufacturing expansion.

• Proprietary enzymatic biologic platform uses proteolytic enzymes from pineapple stem for selective tissue removal.

• Technology validated in 14 clinical trials and recognized by regulatory agencies.

Clinical and commercial progress

• NexoBrid enables rapid burn eschar removal in over 90% of patients, reducing hospital stays and costs, and is used without the need for surgery or anesthesia.

• EscharEx uses the same active ingredient as NexoBrid at half concentration, aiming for chronic wound indications like venous leg ulcers and diabetic foot ulcers.

• US government provided $140 million in non-dilutive funding, recognizing NexoBrid’s value for mass casualty and battlefield use.

• EscharEx Phase III interim readout expected by year-end 2026, with potential label expansion into additional chronic wound indications.

• NexoBrid manufacturing facility expansion expected to resolve supply constraints by mid-2026, supporting global demand.

Financial position and growth outlook

• Holds $54 million in cash, no debt, and benefits from significant US government collaboration funding.

• Facility expansion to be completed in 2026, driving NexoBrid revenue growth through increased capacity and geographic reach.

• EscharEx could generate initial revenue as early as 2028, pending successful Phase III results and regulatory progress.

• BARDA contract expected to conclude in Q1 2026, supporting stockpiling and new indications for NexoBrid.

• No near-term financing pressure due to strong balance sheet and government support.